No Data
No Data
Jiangxi Synergy Pharmaceutical's Antidepression Ingredient Passes China Evaluation
Jiangxi Synergy Pharmaceutical (300636.SZ): The active pharmaceutical ingredient of Agomelatine has been approved by CDE.
On July 22, Gelunhui reported that Jiangxi Synergy Pharmaceutical (300636.SZ) recently obtained information from the National Medical Products Administration's Center for Drug Evaluation (CDE) 'Registration Information Publicity Platform for Pharmaceutical Raw Materials and Excipients.' The company's submission of the active pharmaceutical ingredient for Agomelatine was approved by the CDE.
Jiangxi Synergy Pharmaceutical (300636.SZ): Four multi-functional workshops in Phase I of the Second Factory Area project have been completed and put into production.
On July 22, Gelonhui reported that Jiangxi Synergy Pharmaceutical (300636.SZ) stated on the investor interaction platform that the phase one project of the company's Second Factory Area has a total of four multifunctional workshops, all of which have been completed and put into production. The phase two project has a total of seven workshops and is currently under construction.
Jiangxi Synergy Pharmaceutical's (SZSE:300636) Earnings Growth Rate Lags the 14% CAGR Delivered to Shareholders
List of A-share restricted stocks lifted by Zhongtong | June 27
On June 27, a total of 12 listed companies had their restricted stocks lifted, with a total market value of approximately 4.813 billion yuan. Today's specific unlocking stock situation is as follows: stock name, stock code, restricted stock type and the number of unlocked shares. Dongbei Group 601956 - stock-based incentive, 3.1038 million shares unlocked; Nations Technologies Inc. 300077 - stock-based incentive, 1.496 million shares unlocked; Hubei Zhenhua Chemical 603067 - stock-based incentive, 300,000 shares unlocked; Jiangxi Synergy Pharmaceutical 300636 - stock-based incentive, 1.57 million shares unlocked; IDT Corp 300707 - newly issued A shares - 20 million shares unlocked, corporate shareholders' allotment.
Jiangxi Synergy Pharmaceutical (300636.SZ): 11 active pharmaceutical ingredients passed the on-site inspection for GMP by ANVISA in Brazil.
On June 26th, Gelunhui reported that Jiangxi Synergy Pharmaceutical (300636.SZ) announced that it had accepted an official comprehensive GMP (Drug Production Quality Management Specification) on-site inspection from the Brazilian National Health Surveillance Agency (ANVISA) from April 8th to 13th, 2024. The scope of this inspection includes: active pharmaceutical ingredients: aceclofenac, tapentadol, celecoxib, clopidogrel, febuxostat, fulvestrant, gabapentin, mirabegron, rivaroxaban, tegridol, and voglibose. Recently, the company received a "Drug GMP Certificate" issued by ANVISA.
No Data